Skip to main content
Erschienen in: Annals of Hematology 2/2018

14.10.2017 | Review Article

Current prognostic and predictive factors in follicular lymphoma

verfasst von: Marc Sorigue, Juan-Manuel Sancho

Erschienen in: Annals of Hematology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Follicular lymphoma (FL) is generally considered an indolent disorder. With modern day treatments, long remissions are often achieved both in the front-line and relapsed setting. However, a subset of patients has a more aggressive course and a worse outcome. Their identification is the main purpose of modern day prognostic tools. In this review, we attempt to summarize the evidence concerning prognostic and predictive factors in FL, including (1) pre-treatment factors, from baseline clinical characteristics and imaging tests to histological grade, the microenvironment and genomic abnormalities; (2) post-treatment factors, i.e., depth of response, measured both by imaging tests and minimal residual disease; (3) factors at relapse and duration of response; and (4) prognostic factors in histological transformation. We conclude that, despite the existence of numerous tools, the availability of some of them is still limited; they generally suffer from notable downsides, and most have unproven predictive value, thus having scarce bearing on the choice of regimen at present. However, with the technological and scientific developments of the last few years, the potential for these prognostic factors is promising, particularly in combination, which will probably, in time, help guide therapeutic decisions.
Literatur
2.
Zurück zum Zitat Leich E, Salaverria I, Bea S, Zettl A, Wright G, Moreno V, Gascoyne RD, Chan WC, Braziel RM, Rimsza LM, Weisenburger DD, Delabie J, Jaffe ES, Lister A, Fitzgibbon J, Staudt LM, Hartmann EM, Mueller-Hermelink HK, Campo E, Ott G, Rosenwald A (2009) Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. Blood 114:826–834. https://doi.org/10.1182/blood-2009-01-198580 PubMedPubMedCentralCrossRef Leich E, Salaverria I, Bea S, Zettl A, Wright G, Moreno V, Gascoyne RD, Chan WC, Braziel RM, Rimsza LM, Weisenburger DD, Delabie J, Jaffe ES, Lister A, Fitzgibbon J, Staudt LM, Hartmann EM, Mueller-Hermelink HK, Campo E, Ott G, Rosenwald A (2009) Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. Blood 114:826–834. https://​doi.​org/​10.​1182/​blood-2009-01-198580 PubMedPubMedCentralCrossRef
5.
Zurück zum Zitat Dreyling M, Ghielmini M, Rule S, Salles G, Vitolo U, Ladetto M, ESMO Guidelines Committee (2016) Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27S5:v83–v90CrossRef Dreyling M, Ghielmini M, Rule S, Salles G, Vitolo U, Ladetto M, ESMO Guidelines Committee (2016) Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27S5:v83–v90CrossRef
6.
7.
Zurück zum Zitat Federico M, Luminari S, Dondi A, Tucci A, Vitolo U, Rigacci L, Di Raimondo F, Carella AM, Pulsoni A, Merli F, Arcaini L, Angrilli F, Stelitano C, Gaidano G, Dell'olio M, Marcheselli L, Franco V, Galimberti S, Sacchi S, Brugiatelli M (2013) R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol 31:1506–1513. https://doi.org/10.1200/JCO.2012.45.0866 PubMedCrossRef Federico M, Luminari S, Dondi A, Tucci A, Vitolo U, Rigacci L, Di Raimondo F, Carella AM, Pulsoni A, Merli F, Arcaini L, Angrilli F, Stelitano C, Gaidano G, Dell'olio M, Marcheselli L, Franco V, Galimberti S, Sacchi S, Brugiatelli M (2013) R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol 31:1506–1513. https://​doi.​org/​10.​1200/​JCO.​2012.​45.​0866 PubMedCrossRef
8.
Zurück zum Zitat Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Dürk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W, Study group indolent Lymphomas (StiL) (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381:1203–1210. https://doi.org/10.1016/S0140-6736(12)61763-2 PubMedCrossRef Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Dürk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W, Study group indolent Lymphomas (StiL) (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381:1203–1210. https://​doi.​org/​10.​1016/​S0140-6736(12)61763-2 PubMedCrossRef
9.
Zurück zum Zitat Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS (2014) Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 15:1311–1318. https://doi.org/10.1016/S1470-2045(14)70455-3 PubMedPubMedCentralCrossRef Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS (2014) Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 15:1311–1318. https://​doi.​org/​10.​1016/​S1470-2045(14)70455-3 PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, Hainsworth JD, Maurer MJ, Cerhan JR, Link BK, Zelenetz AD, Friedberg JW (2015) Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol 33:2516–2522. https://doi.org/10.1200/JCO.2014.59.7534 PubMedPubMedCentralCrossRef Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, Hainsworth JD, Maurer MJ, Cerhan JR, Link BK, Zelenetz AD, Friedberg JW (2015) Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol 33:2516–2522. https://​doi.​org/​10.​1200/​JCO.​2014.​59.​7534 PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Sorigue M, Mercadal S, Alonso S, Fernández-Álvarez R, García O, Moreno M, Pomares H, Alcoceba M, González-García E, Motlló C, González-Barca E, Martin A, Sureda A, Caballero D, Ribera JM, Sancho JM (2017) Refractoriness to immunochemotherapy in follicular lymphoma: predictive factors and outcome. Hematol Oncol (in press). https://doi.org/10.1002/hon.2378 Sorigue M, Mercadal S, Alonso S, Fernández-Álvarez R, García O, Moreno M, Pomares H, Alcoceba M, González-García E, Motlló C, González-Barca E, Martin A, Sureda A, Caballero D, Ribera JM, Sancho JM (2017) Refractoriness to immunochemotherapy in follicular lymphoma: predictive factors and outcome. Hematol Oncol (in press). https://​doi.​org/​10.​1002/​hon.​2378
15.
Zurück zum Zitat Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, Au WY, Bellei M, Brice P, Caballero D, Coiffier B, Conde-Garcia E, Doyen C, Federico M, Fisher RI, Garcia-Conde JF, Guglielmi C, Hagenbeek A, Haïoun C, LeBlanc M, Lister AT, Lopez-Guillermo A, McLaughlin P, Milpied N, Morel P, Mounier N, Proctor SJ, Rohatiner A, Smith P, Soubeyran P, Tilly H, Vitolo U, Zinzani PL, Zucca E, Montserrat E (2004) Follicular lymphoma international prognostic index. Blood 104:1258–1265PubMedCrossRef Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, Au WY, Bellei M, Brice P, Caballero D, Coiffier B, Conde-Garcia E, Doyen C, Federico M, Fisher RI, Garcia-Conde JF, Guglielmi C, Hagenbeek A, Haïoun C, LeBlanc M, Lister AT, Lopez-Guillermo A, McLaughlin P, Milpied N, Morel P, Mounier N, Proctor SJ, Rohatiner A, Smith P, Soubeyran P, Tilly H, Vitolo U, Zinzani PL, Zucca E, Montserrat E (2004) Follicular lymphoma international prognostic index. Blood 104:1258–1265PubMedCrossRef
16.
Zurück zum Zitat Davies AJ (2006) Clinical and molecular prognostic factors in follicular lymphoma. Curr Oncol Rep 8:359–367PubMedCrossRef Davies AJ (2006) Clinical and molecular prognostic factors in follicular lymphoma. Curr Oncol Rep 8:359–367PubMedCrossRef
17.
Zurück zum Zitat Federico M, Vitolo U, Zinzani PL, Chisesi T, Clò V, Bellesi G, Magagnoli M, Liberati M, Boccomini C, Niscola P, Pavone V, Cuneo A, Santini G, Brugiatelli M, Baldini L, Rigacci L, Resegotti L (2000) Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi Blood 95:783–789PubMed Federico M, Vitolo U, Zinzani PL, Chisesi T, Clò V, Bellesi G, Magagnoli M, Liberati M, Boccomini C, Niscola P, Pavone V, Cuneo A, Santini G, Brugiatelli M, Baldini L, Rigacci L, Resegotti L (2000) Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi Blood 95:783–789PubMed
19.
Zurück zum Zitat Mihaljevic B, Jelicic J, Andjelic B, Antic D, Markovic O, Petkovic I, Jovanovic MP, Trajkovic G, Bila J, Djurasinovic V, Sretenovic A, Vukovic V, Smiljanic M, Balint MT (2016) FCG (FLIPI, Charlson comorbidity index, and histological grade) score is superior to FLIPI in advanced follicular lymphoma. Int J Hematol 104:692–699. https://doi.org/10.1007/s12185-016-2099-7 PubMedCrossRef Mihaljevic B, Jelicic J, Andjelic B, Antic D, Markovic O, Petkovic I, Jovanovic MP, Trajkovic G, Bila J, Djurasinovic V, Sretenovic A, Vukovic V, Smiljanic M, Balint MT (2016) FCG (FLIPI, Charlson comorbidity index, and histological grade) score is superior to FLIPI in advanced follicular lymphoma. Int J Hematol 104:692–699. https://​doi.​org/​10.​1007/​s12185-016-2099-7 PubMedCrossRef
21.
Zurück zum Zitat Tracy SI, Maurer MJ, Witzig TE, Drake MT, Ansell S, Nowakowski GS, Inwards DJ, Thompson CA, Johnston PB, Micallef I, Allmer C, Macon WR, Weiner GJ, Slager SL, Habermann TM, Link BK, Cerhan JR (2016) Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma. Blood 128:1104 Tracy SI, Maurer MJ, Witzig TE, Drake MT, Ansell S, Nowakowski GS, Inwards DJ, Thompson CA, Johnston PB, Micallef I, Allmer C, Macon WR, Weiner GJ, Slager SL, Habermann TM, Link BK, Cerhan JR (2016) Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma. Blood 128:1104
22.
Zurück zum Zitat Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, Pro B, Pileri S, Pulsoni A, Soubeyran P, Cortelazzo S, Martinelli G, Martelli M, Rigacci L, Arcaini L, Di Raimondo F, Merli F, Sabattini E, McLaughlin P, Solal-Céligny P (2009) Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 27:4555–4562. https://doi.org/10.1200/JCO.2008.21.3991 PubMedCrossRef Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, Pro B, Pileri S, Pulsoni A, Soubeyran P, Cortelazzo S, Martinelli G, Martelli M, Rigacci L, Arcaini L, Di Raimondo F, Merli F, Sabattini E, McLaughlin P, Solal-Céligny P (2009) Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 27:4555–4562. https://​doi.​org/​10.​1200/​JCO.​2008.​21.​3991 PubMedCrossRef
23.
Zurück zum Zitat Nooka AK, Nabhan C, Zhou X, Taylor MD, Byrtek M, Miller TP, Friedberg JW, Zelenetz AD, Link BK, Cerhan JR, Dillon H, Sinha R, Shenoy PJ, Levy D, Dawson K, Hirata JH, Flowers CR (2013) Examination of the follicular lymphoma international prognostic index (FLIPI) in the national LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices. Ann Oncol 24:441–448. https://doi.org/10.1093/annonc/mds429 PubMedCrossRef Nooka AK, Nabhan C, Zhou X, Taylor MD, Byrtek M, Miller TP, Friedberg JW, Zelenetz AD, Link BK, Cerhan JR, Dillon H, Sinha R, Shenoy PJ, Levy D, Dawson K, Hirata JH, Flowers CR (2013) Examination of the follicular lymphoma international prognostic index (FLIPI) in the national LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices. Ann Oncol 24:441–448. https://​doi.​org/​10.​1093/​annonc/​mds429 PubMedCrossRef
24.
Zurück zum Zitat Plancarte F, López-Guillermo A, Arenillas L, Montoto S, Giné E, Muntañola A, Ferrer A, Villamor N, Bosch F, Colomo L, Balaguer O, Campo E, Montserrat E (2006) Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients. Eur J Haematol 76:58–63. https://doi.org/10.1111/j.1600-0609.2005.00564.x PubMedCrossRef Plancarte F, López-Guillermo A, Arenillas L, Montoto S, Giné E, Muntañola A, Ferrer A, Villamor N, Bosch F, Colomo L, Balaguer O, Campo E, Montserrat E (2006) Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients. Eur J Haematol 76:58–63. https://​doi.​org/​10.​1111/​j.​1600-0609.​2005.​00564.​x PubMedCrossRef
25.
Zurück zum Zitat Giné E, Montoto S, Bosch F, Arenillas L, Mercadal S, Villamor N, Martínez A, Colomo L, Campo E, Montserrat E, López-Guillermo A (2006) The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. Ann Oncol 17:1539–1545. https://doi.org/10.1093/annonc/mdl162 PubMedCrossRef Giné E, Montoto S, Bosch F, Arenillas L, Mercadal S, Villamor N, Martínez A, Colomo L, Campo E, Montserrat E, López-Guillermo A (2006) The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. Ann Oncol 17:1539–1545. https://​doi.​org/​10.​1093/​annonc/​mdl162 PubMedCrossRef
26.
Zurück zum Zitat Bastion Y, Berger F, Bryon PA, Felman P, Ffrench M, Coiffier B (1991) Follicular lymphomas: assessment of prognostic factors in 127 patients followed for 10 years. Ann Oncol 2S2:123–129 Bastion Y, Berger F, Bryon PA, Felman P, Ffrench M, Coiffier B (1991) Follicular lymphomas: assessment of prognostic factors in 127 patients followed for 10 years. Ann Oncol 2S2:123–129
29.
Zurück zum Zitat Cabezas-Quintario MA, Gomez P, Yuste-Del Pozo V, Valencia-Mesa AL, Sosa G, Ricard P, Hijas-Gómez AI, Pinedo F, Arguelles M (2016) Bone marrow trephine biopsy involvement by lymphoma: pattern of involvement and concordance with flow cytometry, in 10 years from a single institution. Clin Transl Oncol 18:537–540. https://doi.org/10.1007/s12094-015-1393-9 PubMedCrossRef Cabezas-Quintario MA, Gomez P, Yuste-Del Pozo V, Valencia-Mesa AL, Sosa G, Ricard P, Hijas-Gómez AI, Pinedo F, Arguelles M (2016) Bone marrow trephine biopsy involvement by lymphoma: pattern of involvement and concordance with flow cytometry, in 10 years from a single institution. Clin Transl Oncol 18:537–540. https://​doi.​org/​10.​1007/​s12094-015-1393-9 PubMedCrossRef
30.
Zurück zum Zitat Kato D, Yoshioka S, Yabushita T, Shimomura Y, Ono Y, Hiramoto N, Yonetani N, Matsushita A, Hashimoto H, Ishikawa T (2016) The clinical impact of minimal bone marrow involvement on the outcome of patients with follicular lymphoma. Blood 128:2966CrossRef Kato D, Yoshioka S, Yabushita T, Shimomura Y, Ono Y, Hiramoto N, Yonetani N, Matsushita A, Hashimoto H, Ishikawa T (2016) The clinical impact of minimal bone marrow involvement on the outcome of patients with follicular lymphoma. Blood 128:2966CrossRef
31.
Zurück zum Zitat Galimberti S, Luminari S, Ciabatti E, Grassi S, Guerrini F, Dondi A, Marcheselli L, Ladetto M, Piccaluga PP, Gazzola A, Mannu C, Monitillo L, Mantoan B, Del Giudice I, Della Starza I, Cavalli M, Arcaini L, Tucci A, Palumbo GA, Rigacci L, Pulsoni A, Vitolo U, Boccomini C, Vallisa D, Bertoldero G, Gaidano G, Musto P, Petrini M, Federico M (2014) Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial. Clin Cancer Res 20:6398–6405. https://doi.org/10.1158/1078-0432.CCR-14-0407 PubMedCrossRef Galimberti S, Luminari S, Ciabatti E, Grassi S, Guerrini F, Dondi A, Marcheselli L, Ladetto M, Piccaluga PP, Gazzola A, Mannu C, Monitillo L, Mantoan B, Del Giudice I, Della Starza I, Cavalli M, Arcaini L, Tucci A, Palumbo GA, Rigacci L, Pulsoni A, Vitolo U, Boccomini C, Vallisa D, Bertoldero G, Gaidano G, Musto P, Petrini M, Federico M (2014) Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial. Clin Cancer Res 20:6398–6405. https://​doi.​org/​10.​1158/​1078-0432.​CCR-14-0407 PubMedCrossRef
32.
Zurück zum Zitat van Oers MH, Tönnissen E, Van Glabbeke M, Giurgea L, Jansen JH, Klasa R, Marcus RE, Wolf M, Kimby E, Vranovsky A, Holte H, Hagenbeek A, van der Reijden BA (2010) BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study. J Clin Oncol 28:2246–2252. https://doi.org/10.1200/JCO.2009.25.0852 PubMedCrossRef van Oers MH, Tönnissen E, Van Glabbeke M, Giurgea L, Jansen JH, Klasa R, Marcus RE, Wolf M, Kimby E, Vranovsky A, Holte H, Hagenbeek A, van der Reijden BA (2010) BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study. J Clin Oncol 28:2246–2252. https://​doi.​org/​10.​1200/​JCO.​2009.​25.​0852 PubMedCrossRef
33.
Zurück zum Zitat Rambaldi A, Carlotti E, Oldani E, Della Starza I, Baccarani M, Cortelazzo S, Lauria F, Arcaini L, Morra E, Pulsoni A, Rigacci L, Rupolo M, Zaja F, Zinzani PL, Barbui T, Foa R (2005) Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma. Blood 105:3428–3433. https://doi.org/10.1182/blood-2004-06-2490 PubMedCrossRef Rambaldi A, Carlotti E, Oldani E, Della Starza I, Baccarani M, Cortelazzo S, Lauria F, Arcaini L, Morra E, Pulsoni A, Rigacci L, Rupolo M, Zaja F, Zinzani PL, Barbui T, Foa R (2005) Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma. Blood 105:3428–3433. https://​doi.​org/​10.​1182/​blood-2004-06-2490 PubMedCrossRef
34.
Zurück zum Zitat Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A, Pulsoni A, Musso M, Liberati AM, Olivieri A, Gallamini A, Pogliani E, Rota Scalabrini D, Callea V, Di Raimondo F, Pavone V, Tucci A, Cortelazzo S, Levis A, Boccadoro M, Majolino I, Pileri A, Gianni AM, Passera R, Corradini P, Tarella C, Gruppo Italiano Trapianto di Midollo Osseo (GITMO).; Intergruppo Italiano Linfomi (IIL) (2008) Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 111:4004–4013. https://doi.org/10.1182/blood-2007-10-116749 PubMedCrossRef Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A, Pulsoni A, Musso M, Liberati AM, Olivieri A, Gallamini A, Pogliani E, Rota Scalabrini D, Callea V, Di Raimondo F, Pavone V, Tucci A, Cortelazzo S, Levis A, Boccadoro M, Majolino I, Pileri A, Gianni AM, Passera R, Corradini P, Tarella C, Gruppo Italiano Trapianto di Midollo Osseo (GITMO).; Intergruppo Italiano Linfomi (IIL) (2008) Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 111:4004–4013. https://​doi.​org/​10.​1182/​blood-2007-10-116749 PubMedCrossRef
35.
Zurück zum Zitat Ladetto M, Lobetti-Bodoni C, Mantoan B, Ceccarelli M, Boccomini C, Genuardi E, Chiappella A, Baldini L, Rossi G, Pulsoni A, Di Raimondo F, Rigacci L, Pinto A, Galimberti S, Bari A, Rota-Scalabrini D, Ferrari A, Zaja F, Gallamini A, Specchia G, Musto P, Rossi FG, Gamba E, Evangelista A, Vitolo U, Fondazione Italiana Linfomi (2013) Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. Blood 122:3759–3766. https://doi.org/10.1182/blood-2013-06-507319 PubMedCrossRef Ladetto M, Lobetti-Bodoni C, Mantoan B, Ceccarelli M, Boccomini C, Genuardi E, Chiappella A, Baldini L, Rossi G, Pulsoni A, Di Raimondo F, Rigacci L, Pinto A, Galimberti S, Bari A, Rota-Scalabrini D, Ferrari A, Zaja F, Gallamini A, Specchia G, Musto P, Rossi FG, Gamba E, Evangelista A, Vitolo U, Fondazione Italiana Linfomi (2013) Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. Blood 122:3759–3766. https://​doi.​org/​10.​1182/​blood-2013-06-507319 PubMedCrossRef
36.
Zurück zum Zitat Zohren F, Bruns I, Pechtel S, Schroeder T, Fenk R, Czibere A, Maschmeyer G, Kofahl-Krause D, Niederle N, Heil G, Losem C, Welslau M, Brugger W, Germing U, Kronenwett R, Barth J, Rummel MJ, Haas R, Kobbe G (2015) Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy. Blood 126:1407–1414PubMedCrossRef Zohren F, Bruns I, Pechtel S, Schroeder T, Fenk R, Czibere A, Maschmeyer G, Kofahl-Krause D, Niederle N, Heil G, Losem C, Welslau M, Brugger W, Germing U, Kronenwett R, Barth J, Rummel MJ, Haas R, Kobbe G (2015) Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy. Blood 126:1407–1414PubMedCrossRef
37.
Zurück zum Zitat Pott C, Hoster E, Kehden B, Unterhalt M, Herold M, van der Jagt RH, Janssens A, Kneba M, Mayer J, Pocock C, Danesi N, Fingerle-Rowson G, Harbron C, Mundt K, Marcus RE, Hiddemann W (2016) Minimal residual disease in patients with follicular lymphoma treated with obinutuzumab or rituximab as first-line induction Immunochemotherapy and maintenance in the phase 3 GALLIUM study. Blood 128:613CrossRef Pott C, Hoster E, Kehden B, Unterhalt M, Herold M, van der Jagt RH, Janssens A, Kneba M, Mayer J, Pocock C, Danesi N, Fingerle-Rowson G, Harbron C, Mundt K, Marcus RE, Hiddemann W (2016) Minimal residual disease in patients with follicular lymphoma treated with obinutuzumab or rituximab as first-line induction Immunochemotherapy and maintenance in the phase 3 GALLIUM study. Blood 128:613CrossRef
39.
Zurück zum Zitat Nakajima Y, Fujisawa S, Nigauri C, Haruka T, Matsumura A, Ando T, Suzuki T, Yamamoto E, Ogusa E, Ishii Y, Takahashi H, Miyashita K, Watanabe R, Miyazaki T, Motohashi K, Fujita A, Hagihara M, Matsumoto K, Nakajima H (2016) Identification of bone marrow involvement of FL: comparison of PET-CT and bone marrow biopsy. Blood 128:2970 Nakajima Y, Fujisawa S, Nigauri C, Haruka T, Matsumura A, Ando T, Suzuki T, Yamamoto E, Ogusa E, Ishii Y, Takahashi H, Miyashita K, Watanabe R, Miyazaki T, Motohashi K, Fujita A, Hagihara M, Matsumoto K, Nakajima H (2016) Identification of bone marrow involvement of FL: comparison of PET-CT and bone marrow biopsy. Blood 128:2970
40.
Zurück zum Zitat Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA, Alliance, Australasian Leukaemia and Lymphoma Group.; Eastern Cooperative Oncology Group.; European Mantle Cell Lymphoma Consortium.; Italian Lymphoma Foundation.; European Organisation for Research.; Treatment of Cancer/Dutch Hemato-Oncology Group.; Grupo Español de Médula Ósea.; German High-Grade Lymphoma Study Group.; German Hodgkin's Study Group.; Japanese Lymphorra Study Group.; Lymphoma Study Association.; NCIC Clinical Trials Group.; Nordic Lymphoma Study Group.; Southwest Oncology Group.; United Kingdom National Cancer Research Institute (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059–3068. https://doi.org/10.1200/JCO.2013.54.8800 PubMedPubMedCentralCrossRef Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA, Alliance, Australasian Leukaemia and Lymphoma Group.; Eastern Cooperative Oncology Group.; European Mantle Cell Lymphoma Consortium.; Italian Lymphoma Foundation.; European Organisation for Research.; Treatment of Cancer/Dutch Hemato-Oncology Group.; Grupo Español de Médula Ósea.; German High-Grade Lymphoma Study Group.; German Hodgkin's Study Group.; Japanese Lymphorra Study Group.; Lymphoma Study Association.; NCIC Clinical Trials Group.; Nordic Lymphoma Study Group.; Southwest Oncology Group.; United Kingdom National Cancer Research Institute (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059–3068. https://​doi.​org/​10.​1200/​JCO.​2013.​54.​8800 PubMedPubMedCentralCrossRef
42.
Zurück zum Zitat Meignan M, Cottereau AS, Versari A, Chartier L, Dupuis J, Boussetta S, Grassi I, Casasnovas RO, Haioun C, Tilly H, Tarantino V, Dubreuil J, Federico M, Salles G, Luminari S, Trotman J (2016) Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies. J Clin Oncol 34:3618–3626. https://doi.org/10.1200/JCO.2016.66.9440 CrossRef Meignan M, Cottereau AS, Versari A, Chartier L, Dupuis J, Boussetta S, Grassi I, Casasnovas RO, Haioun C, Tilly H, Tarantino V, Dubreuil J, Federico M, Salles G, Luminari S, Trotman J (2016) Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies. J Clin Oncol 34:3618–3626. https://​doi.​org/​10.​1200/​JCO.​2016.​66.​9440 CrossRef
45.
Zurück zum Zitat Cottereau AS, Versari A, Chartier L, Dupuis J, Tarantino V, Casasnovas RO, Franceschetto A, Itti E, Tilly H, Haioun C, Federico M, Berriolo A, Salles G, Luminari S, Meignan M, Trotman J (2016) Low Suvmax measured on baseline FDG-PET/CT and elevated β2 microglobulin are negative predictors of outcome in high tumor burden follicular lymphoma treated by immunochemotherapy: a pooled analysis of three prospective studies. Blood 128:1101CrossRef Cottereau AS, Versari A, Chartier L, Dupuis J, Tarantino V, Casasnovas RO, Franceschetto A, Itti E, Tilly H, Haioun C, Federico M, Berriolo A, Salles G, Luminari S, Meignan M, Trotman J (2016) Low Suvmax measured on baseline FDG-PET/CT and elevated β2 microglobulin are negative predictors of outcome in high tumor burden follicular lymphoma treated by immunochemotherapy: a pooled analysis of three prospective studies. Blood 128:1101CrossRef
46.
Zurück zum Zitat Ott G, Katzenberger T, Lohr A, Kindelberger S, Rüdiger T, Wilhelm M, Kalla J, Rosenwald A, Müller JG, Ott MM, Müller-Hermelink HK (2002) Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood 99:3806–3812PubMedCrossRef Ott G, Katzenberger T, Lohr A, Kindelberger S, Rüdiger T, Wilhelm M, Kalla J, Rosenwald A, Müller JG, Ott MM, Müller-Hermelink HK (2002) Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood 99:3806–3812PubMedCrossRef
47.
Zurück zum Zitat Piccaluga PP, Califano A, Klein U, Agostinelli C, Bellosillo B, Gimeno E, Serrano S, Solè F, Zang Y, Falini B, Zinzani PL, Pileri SA (2008) Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas. Haematologica 93:1033–1038. https://doi.org/10.3324/haematol.12754 PubMedCrossRef Piccaluga PP, Califano A, Klein U, Agostinelli C, Bellosillo B, Gimeno E, Serrano S, Solè F, Zang Y, Falini B, Zinzani PL, Pileri SA (2008) Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas. Haematologica 93:1033–1038. https://​doi.​org/​10.​3324/​haematol.​12754 PubMedCrossRef
50.
Zurück zum Zitat Leich E, Hoster E, Wartenberg M, Unterhalt M, Siebert R, Koch K, Klapper W, Engelhard M, Puppe B, Horn H, Staiger AM, Stuhlmann-Laeisz C, Bernd HW, Feller AC, Hummel M, Lenze D, Stein H, Hartmann S, Hansmann ML, Möller P, Hiddemann W, Dreyling M, Ott G, Rosenwald A, German Low Grade Lymphoma Study Group (GLSG) (2016) Similar clinical features in follicular lymphomas with and without breaks in the BCL2 locus. Leukemia 30:854–860. https://doi.org/10.1038/leu.2015.330 PubMedCrossRef Leich E, Hoster E, Wartenberg M, Unterhalt M, Siebert R, Koch K, Klapper W, Engelhard M, Puppe B, Horn H, Staiger AM, Stuhlmann-Laeisz C, Bernd HW, Feller AC, Hummel M, Lenze D, Stein H, Hartmann S, Hansmann ML, Möller P, Hiddemann W, Dreyling M, Ott G, Rosenwald A, German Low Grade Lymphoma Study Group (GLSG) (2016) Similar clinical features in follicular lymphomas with and without breaks in the BCL2 locus. Leukemia 30:854–860. https://​doi.​org/​10.​1038/​leu.​2015.​330 PubMedCrossRef
51.
Zurück zum Zitat Hans CP, Weisenburger DD, Vose JM, Hock LM, Lynch JC, Aoun P, Greiner TC, Chan WC, Bociek RG, Bierman PJ, Armitage JO (2003) A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood 101:2363–2367. https://doi.org/10.1182/blood-2002-07-2298 PubMedCrossRef Hans CP, Weisenburger DD, Vose JM, Hock LM, Lynch JC, Aoun P, Greiner TC, Chan WC, Bociek RG, Bierman PJ, Armitage JO (2003) A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood 101:2363–2367. https://​doi.​org/​10.​1182/​blood-2002-07-2298 PubMedCrossRef
53.
Zurück zum Zitat Ganti AK, Weisenburger DD, Smith LM, Hans CP, Bociek RG, Bierman PJ, Vose JM, Armitage JO (2006) Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience. Ann Oncol 17:920–927. https://doi.org/10.1093/annonc/mdl039 PubMedCrossRef Ganti AK, Weisenburger DD, Smith LM, Hans CP, Bociek RG, Bierman PJ, Vose JM, Armitage JO (2006) Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience. Ann Oncol 17:920–927. https://​doi.​org/​10.​1093/​annonc/​mdl039 PubMedCrossRef
55.
Zurück zum Zitat Wahlin BE, Sundström C, Sander B, Christensson B, Jeppsson-Ahlberg Å, Hjalmarsson E, Holte H, Østenstad B, Brown PD, Smeland EB, Kimby E (2014) Higher World Health Organization grades of follicular lymphoma correlate with better outcome in two Nordic Lymphoma Group trials of rituximab without chemotherapy. Leuk Lymphoma 55:288–295. https://doi.org/10.3109/10428194.2013.802778 PubMedCrossRef Wahlin BE, Sundström C, Sander B, Christensson B, Jeppsson-Ahlberg Å, Hjalmarsson E, Holte H, Østenstad B, Brown PD, Smeland EB, Kimby E (2014) Higher World Health Organization grades of follicular lymphoma correlate with better outcome in two Nordic Lymphoma Group trials of rituximab without chemotherapy. Leuk Lymphoma 55:288–295. https://​doi.​org/​10.​3109/​10428194.​2013.​802778 PubMedCrossRef
56.
Zurück zum Zitat Tomita N, Takasaki H, Fujisawa S, Miyashita K, Ogusa E, Kishimoto K, Matsuura S, Sakai R, Koharazawa H, Yamamoto W, Fujimaki K, Fujita H, Ishii Y, Taguchi J, Kuwabara H, Motomura S, Ishigatsubo Y (2013) Standard R-CHOP therapy in follicular lymphoma and diffuse large B-cell lymphoma. J Clin Exp Hematop 53:121–125PubMedCrossRef Tomita N, Takasaki H, Fujisawa S, Miyashita K, Ogusa E, Kishimoto K, Matsuura S, Sakai R, Koharazawa H, Yamamoto W, Fujimaki K, Fujita H, Ishii Y, Taguchi J, Kuwabara H, Motomura S, Ishigatsubo Y (2013) Standard R-CHOP therapy in follicular lymphoma and diffuse large B-cell lymphoma. J Clin Exp Hematop 53:121–125PubMedCrossRef
57.
Zurück zum Zitat Koch K, Hoster E, Ziepert M, Unterhalt M, Ott G, Rosenwald A, Hansmann ML, Bernd W, Stein H, Pöschel V, Dreyling M, Trümper L, Löffler M, Schmitz N, Hiddemann W, Pfreundschuh M, Klapper W (2016) Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL. Ann Oncol 27:1323–1329. https://doi.org/10.1093/annonc/mdw185 PubMedCrossRef Koch K, Hoster E, Ziepert M, Unterhalt M, Ott G, Rosenwald A, Hansmann ML, Bernd W, Stein H, Pöschel V, Dreyling M, Trümper L, Löffler M, Schmitz N, Hiddemann W, Pfreundschuh M, Klapper W (2016) Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL. Ann Oncol 27:1323–1329. https://​doi.​org/​10.​1093/​annonc/​mdw185 PubMedCrossRef
58.
Zurück zum Zitat Mercadal S, Pomares H, Sancho JM, Climent F, García O, Encuentra M, Domingo-Doménech E, Sorigué M, Moreno M, Oliveira AC, Ribera JM, Fernández de Sevilla A, González-Barca E (2016) Clinico-biological features, treatment and survival of 457 patients with histological grades 3A and 1-2 follicular lymphoma mostly treated with immunochemotherapy. Br J Haematol 172:470–473. https://doi.org/10.1111/bjh.13502 PubMedCrossRef Mercadal S, Pomares H, Sancho JM, Climent F, García O, Encuentra M, Domingo-Doménech E, Sorigué M, Moreno M, Oliveira AC, Ribera JM, Fernández de Sevilla A, González-Barca E (2016) Clinico-biological features, treatment and survival of 457 patients with histological grades 3A and 1-2 follicular lymphoma mostly treated with immunochemotherapy. Br J Haematol 172:470–473. https://​doi.​org/​10.​1111/​bjh.​13502 PubMedCrossRef
61.
Zurück zum Zitat Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, Miller TP, LeBlanc M, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Connors JM, Lansdorp PM, Ouyang Q, Lister TA, Davies AJ, Norton AJ, Muller-Hermelink HK, Ott G, Campo E, Montserrat E, Wilson WH, Jaffe ES, Simon R, Yang L, Powell J, Zhao H, Goldschmidt N, Chiorazzi M, Staudt LM (2004) Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351:2159–2169. https://doi.org/10.1056/NEJMoa041869 PubMedCrossRef Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, Miller TP, LeBlanc M, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Connors JM, Lansdorp PM, Ouyang Q, Lister TA, Davies AJ, Norton AJ, Muller-Hermelink HK, Ott G, Campo E, Montserrat E, Wilson WH, Jaffe ES, Simon R, Yang L, Powell J, Zhao H, Goldschmidt N, Chiorazzi M, Staudt LM (2004) Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351:2159–2169. https://​doi.​org/​10.​1056/​NEJMoa041869 PubMedCrossRef
65.
Zurück zum Zitat Farinha P, Masoudi H, Skinnider BF, Shumansky K, Spinelli JJ, Gill K, Klasa R, Voss N, Connors JM, Gascoyne RD (2005) Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 106:2169–2174. https://doi.org/10.1182/blood-2005-04-1565 PubMedCrossRef Farinha P, Masoudi H, Skinnider BF, Shumansky K, Spinelli JJ, Gill K, Klasa R, Voss N, Connors JM, Gascoyne RD (2005) Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 106:2169–2174. https://​doi.​org/​10.​1182/​blood-2005-04-1565 PubMedCrossRef
67.
Zurück zum Zitat Canioni D, Salles G, Mounier N, Brousse N, Keuppens M, Morchhauser F, Lamy T, Sonet A, Rousselet MC, Foussard C, Xerri L (2008) High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol 26:440–446. https://doi.org/10.1200/JCO.2007.12.8298 PubMedCrossRef Canioni D, Salles G, Mounier N, Brousse N, Keuppens M, Morchhauser F, Lamy T, Sonet A, Rousselet MC, Foussard C, Xerri L (2008) High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol 26:440–446. https://​doi.​org/​10.​1200/​JCO.​2007.​12.​8298 PubMedCrossRef
68.
Zurück zum Zitat Kridel R, Xerri L, Gelas-Dore B, Tan K, Feugier P, Vawda A, Canioni D, Farinha P, Boussetta S, Moccia AA, Brice P, Chavez EA, Kyle AH, Scott DW, Sanders AD, Fabiani B, Slack GW, Minchinton AI, Haioun C, Connors JM, Sehn LH, Steidl C, Gascoyne RD, Salles G (2015) The prognostic impact of CD163-positive macrophages in follicular lymphoma: a study from the BC Cancer Agency and the Lymphoma Study Association. Clin Cancer Res 21:3428–3435. https://doi.org/10.1158/1078-0432.CCR-14-3253 PubMedCrossRef Kridel R, Xerri L, Gelas-Dore B, Tan K, Feugier P, Vawda A, Canioni D, Farinha P, Boussetta S, Moccia AA, Brice P, Chavez EA, Kyle AH, Scott DW, Sanders AD, Fabiani B, Slack GW, Minchinton AI, Haioun C, Connors JM, Sehn LH, Steidl C, Gascoyne RD, Salles G (2015) The prognostic impact of CD163-positive macrophages in follicular lymphoma: a study from the BC Cancer Agency and the Lymphoma Study Association. Clin Cancer Res 21:3428–3435. https://​doi.​org/​10.​1158/​1078-0432.​CCR-14-3253 PubMedCrossRef
69.
Zurück zum Zitat Carreras J, Lopez-Guillermo A, Roncador G, Villamor N, Colomo L, Martinez A, Hamoudi R, Howat WJ, Montserrat E, Campo E (2009) High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J Clin Oncol 27:1470–1476. https://doi.org/10.1200/JCO.2008.18.0513 PubMedCrossRef Carreras J, Lopez-Guillermo A, Roncador G, Villamor N, Colomo L, Martinez A, Hamoudi R, Howat WJ, Montserrat E, Campo E (2009) High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J Clin Oncol 27:1470–1476. https://​doi.​org/​10.​1200/​JCO.​2008.​18.​0513 PubMedCrossRef
71.
Zurück zum Zitat Sohani AR, Pitcher B, Chadburn A, Said JW, Martin P, Czuczman MS, Bartlett NL, Rosenbaum CA, Leonard JP, Cheson BD, Hsi ED (2015) Interfollicular CD10 expression and follicular PD1 tumor-infiltrating lymphocytes as biologic risk factors in patients with previously untreated follicular lymphoma receiving rituximab-based biologic therapy: an Alliance Correlative Science Study (CALGB 50901, 50402, 50701, 50803, 50401). Blood 126:334 Sohani AR, Pitcher B, Chadburn A, Said JW, Martin P, Czuczman MS, Bartlett NL, Rosenbaum CA, Leonard JP, Cheson BD, Hsi ED (2015) Interfollicular CD10 expression and follicular PD1 tumor-infiltrating lymphocytes as biologic risk factors in patients with previously untreated follicular lymphoma receiving rituximab-based biologic therapy: an Alliance Correlative Science Study (CALGB 50901, 50402, 50701, 50803, 50401). Blood 126:334
73.
Zurück zum Zitat Mitsui T, Yokohama A, Koiso H, Saito A, Toyama K, Shimizu H, Ishizaki T, Irisawa H, Saito T, Murayama K, Matsumoto M, Handa H, Murakami H, Tsukamoto N (2016) Prognostic value of chromosomal abnormalities for follicular lymphoma in the rituximab era. Blood 128:1791 Mitsui T, Yokohama A, Koiso H, Saito A, Toyama K, Shimizu H, Ishizaki T, Irisawa H, Saito T, Murayama K, Matsumoto M, Handa H, Murakami H, Tsukamoto N (2016) Prognostic value of chromosomal abnormalities for follicular lymphoma in the rituximab era. Blood 128:1791
76.
Zurück zum Zitat Cheung KJ, Shah SP, Steidl C, Johnson N, Relander T, Telenius A, Lai B, Murphy KP, Lam W, Al-Tourah AJ, Connors JM, Ng RT, Gascoyne RD, Horsman DE (2009) Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances. Blood 113:137–148. https://doi.org/10.1182/blood-2008-02-140616 PubMedCrossRef Cheung KJ, Shah SP, Steidl C, Johnson N, Relander T, Telenius A, Lai B, Murphy KP, Lam W, Al-Tourah AJ, Connors JM, Ng RT, Gascoyne RD, Horsman DE (2009) Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances. Blood 113:137–148. https://​doi.​org/​10.​1182/​blood-2008-02-140616 PubMedCrossRef
77.
Zurück zum Zitat Schwaenen C, Viardot A, Berger H, Barth TF, Bentink S, Döhner H, Enz M, Feller AC, Hansmann ML, Hummel M, Kestler HA, Klapper W, Kreuz M, Lenze D, Loeffler M, Möller P, Müller-Hermelink HK, Ott G, Rosolowski M, Rosenwald A, Ruf S, Siebert R, Spang R, Stein H, Truemper L, Lichter P, Bentz M, Wessendorf S, Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe (2009) Microarray-based genomic profiling reveals novel genomic aberrations in follicular lymphoma which associate with patient survival and gene expression status. Genes Chromosomes Cancer 48:39–54. https://doi.org/10.1002/gcc.20617 PubMedCrossRef Schwaenen C, Viardot A, Berger H, Barth TF, Bentink S, Döhner H, Enz M, Feller AC, Hansmann ML, Hummel M, Kestler HA, Klapper W, Kreuz M, Lenze D, Loeffler M, Möller P, Müller-Hermelink HK, Ott G, Rosolowski M, Rosenwald A, Ruf S, Siebert R, Spang R, Stein H, Truemper L, Lichter P, Bentz M, Wessendorf S, Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe (2009) Microarray-based genomic profiling reveals novel genomic aberrations in follicular lymphoma which associate with patient survival and gene expression status. Genes Chromosomes Cancer 48:39–54. https://​doi.​org/​10.​1002/​gcc.​20617 PubMedCrossRef
78.
Zurück zum Zitat Eide MB, Liestøl K, Lingjaerde OC, Hystad ME, Kresse SH, Meza-Zepeda L, Myklebost O, Trøen G, Aamot HV, Holte H, Smeland EB, Delabie J (2010) Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones. Blood 116:1489–1497. https://doi.org/10.1182/blood-2010-03-272278 PubMedCrossRef Eide MB, Liestøl K, Lingjaerde OC, Hystad ME, Kresse SH, Meza-Zepeda L, Myklebost O, Trøen G, Aamot HV, Holte H, Smeland EB, Delabie J (2010) Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones. Blood 116:1489–1497. https://​doi.​org/​10.​1182/​blood-2010-03-272278 PubMedCrossRef
79.
Zurück zum Zitat Bouska A, McKeithan TW, Deffenbacher KE, Lachel C, Wright GW, Iqbal J, Smith LM, Zhang W, Kucuk C, Rinaldi A, Bertoni F, Fitzgibbon J, Fu K, Weisenburger DD, Greiner TC, Dave BJ, Gascoyne RD, Rosenwald A, Ott G, Campo E, Rimsza LM, Delabie J, Jaffe ES, Braziel RM, Connors JM, Staudt LM, Chan WC (2014) Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. Blood 123:1681–1690. https://doi.org/10.1182/blood-2013-05-500595 PubMedPubMedCentralCrossRef Bouska A, McKeithan TW, Deffenbacher KE, Lachel C, Wright GW, Iqbal J, Smith LM, Zhang W, Kucuk C, Rinaldi A, Bertoni F, Fitzgibbon J, Fu K, Weisenburger DD, Greiner TC, Dave BJ, Gascoyne RD, Rosenwald A, Ott G, Campo E, Rimsza LM, Delabie J, Jaffe ES, Braziel RM, Connors JM, Staudt LM, Chan WC (2014) Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. Blood 123:1681–1690. https://​doi.​org/​10.​1182/​blood-2013-05-500595 PubMedPubMedCentralCrossRef
80.
Zurück zum Zitat Bouska A, Zhang W, Gong Q, Iqbal J, Scuto A, Vose J, Ludvigsen M, Fu K, Weisenburger DD, Greiner TC, Gascoyne RD, Rosenwald A, Ott G, Campo E, Rimsza LM, Delabie J, Jaffe ES, Braziel RM, Connors JM, Wu CI, Staudt LM, D'Amore F, McKeithan TW, Chan WC (2017) Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma. Leukemia 31:83–91. https://doi.org/10.1038/leu.2016.175 PubMedCrossRef Bouska A, Zhang W, Gong Q, Iqbal J, Scuto A, Vose J, Ludvigsen M, Fu K, Weisenburger DD, Greiner TC, Gascoyne RD, Rosenwald A, Ott G, Campo E, Rimsza LM, Delabie J, Jaffe ES, Braziel RM, Connors JM, Wu CI, Staudt LM, D'Amore F, McKeithan TW, Chan WC (2017) Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma. Leukemia 31:83–91. https://​doi.​org/​10.​1038/​leu.​2016.​175 PubMedCrossRef
82.
Zurück zum Zitat Tsukamoto T, Kiyota M, Kawata E, Uoshima N, Tatekawa S, Chinen Y, Nagoshi H, Mizutani S, Shimura Y, Yamamoto-Sugitani M, Kobayashi T, Horiike S, Yasukawa S, Yanagisawa A, Taniwaki M, Kuroda J (2017) Detection of chromosomal abnormalities by G-banding and prognostic impact in follicular lymphoma in the rituximab era. Int J Hematol 105:658–667. https://doi.org/10.1007/s12185-016-2166-0 PubMedCrossRef Tsukamoto T, Kiyota M, Kawata E, Uoshima N, Tatekawa S, Chinen Y, Nagoshi H, Mizutani S, Shimura Y, Yamamoto-Sugitani M, Kobayashi T, Horiike S, Yasukawa S, Yanagisawa A, Taniwaki M, Kuroda J (2017) Detection of chromosomal abnormalities by G-banding and prognostic impact in follicular lymphoma in the rituximab era. Int J Hematol 105:658–667. https://​doi.​org/​10.​1007/​s12185-016-2166-0 PubMedCrossRef
86.
Zurück zum Zitat O'Shea D, O'Riain C, Taylor C, Waters R, Carlotti E, Macdougall F, Gribben J, Rosenwald A, Ott G, Rimsza LM, Smeland EB, Johnson N, Campo E, Greiner TC, Chan WC, Gascoyne RD, Wright G, Staudt LM, Lister TA, Fitzgibbon J (2008) The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. Blood 112:3126–3129. https://doi.org/10.1182/blood-2008-05-154013 PubMedPubMedCentralCrossRef O'Shea D, O'Riain C, Taylor C, Waters R, Carlotti E, Macdougall F, Gribben J, Rosenwald A, Ott G, Rimsza LM, Smeland EB, Johnson N, Campo E, Greiner TC, Chan WC, Gascoyne RD, Wright G, Staudt LM, Lister TA, Fitzgibbon J (2008) The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. Blood 112:3126–3129. https://​doi.​org/​10.​1182/​blood-2008-05-154013 PubMedPubMedCentralCrossRef
87.
Zurück zum Zitat Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M, Pott C, Kopp N, Murakami M, Horn H, Leich E, Moccia AA, Mottok A, Sunkavalli A, Van Hummelen P, Ducar M, Ennishi D, Shulha HP, Hother C, Connors JM, Sehn LH, Dreyling M, Neuberg D, Möller P, Feller AC, Hansmann ML, Stein H, Rosenwald A, Ott G, Klapper W, Unterhalt M, Hiddemann W, Gascoyne RD, Weinstock DM, Weigert O (2015) Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol 16:1111–1122. https://doi.org/10.1016/S1470-2045(15)00169-2 PubMedCrossRef Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M, Pott C, Kopp N, Murakami M, Horn H, Leich E, Moccia AA, Mottok A, Sunkavalli A, Van Hummelen P, Ducar M, Ennishi D, Shulha HP, Hother C, Connors JM, Sehn LH, Dreyling M, Neuberg D, Möller P, Feller AC, Hansmann ML, Stein H, Rosenwald A, Ott G, Klapper W, Unterhalt M, Hiddemann W, Gascoyne RD, Weinstock DM, Weigert O (2015) Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol 16:1111–1122. https://​doi.​org/​10.​1016/​S1470-2045(15)00169-2 PubMedCrossRef
89.
Zurück zum Zitat Kridel R, Chan FC, Mottok A, Boyle M, Farinha P, Tan K, Meissner B, Bashashati A, McPherson A, Roth A, Shumansky K, Yap D, Ben-Neriah S, Rosner J, Smith MA, Nielsen C, Giné E, Telenius A, Ennishi D, Mungall A, Moore R, Morin RD, Johnson NA, Sehn LH, Tousseyn T, Dogan A, Connors JM, Scott DW, Steidl C, Marra MA, Gascoyne RD, Shah SP (2016) Histological transformation and progression in follicular lymphoma: a clonal evolution study. PLoS Med 13:e1002197. https://doi.org/10.1371/journal.pmed.1002197 PubMedPubMedCentralCrossRef Kridel R, Chan FC, Mottok A, Boyle M, Farinha P, Tan K, Meissner B, Bashashati A, McPherson A, Roth A, Shumansky K, Yap D, Ben-Neriah S, Rosner J, Smith MA, Nielsen C, Giné E, Telenius A, Ennishi D, Mungall A, Moore R, Morin RD, Johnson NA, Sehn LH, Tousseyn T, Dogan A, Connors JM, Scott DW, Steidl C, Marra MA, Gascoyne RD, Shah SP (2016) Histological transformation and progression in follicular lymphoma: a clonal evolution study. PLoS Med 13:e1002197. https://​doi.​org/​10.​1371/​journal.​pmed.​1002197 PubMedPubMedCentralCrossRef
90.
Zurück zum Zitat Jurinovic V, Kridel R, Staiger AM, Szczepanowski M, Horn H, Dreyling MH, Rosenwald A, Ott G, Klapper W, Zelenetz AD, Barr PM, Friedberg JW, Ansell S, Sehn LH, Connors JM, Gascoyne RD, Hiddemann W, Unterhalt M, Weinstock DM, Weigert O (2016) Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood 128:1112–1120PubMedPubMedCentralCrossRef Jurinovic V, Kridel R, Staiger AM, Szczepanowski M, Horn H, Dreyling MH, Rosenwald A, Ott G, Klapper W, Zelenetz AD, Barr PM, Friedberg JW, Ansell S, Sehn LH, Connors JM, Gascoyne RD, Hiddemann W, Unterhalt M, Weinstock DM, Weigert O (2016) Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood 128:1112–1120PubMedPubMedCentralCrossRef
92.
Zurück zum Zitat Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, Johnson NA, Severson TM, Chiu R, Field M, Jackman S, Krzywinski M, Scott DW, Trinh DL, Tamura-Wells J, Li S, Firme MR, Rogic S, Griffith M, Chan S, Yakovenko O, Meyer IM, Zhao EY, Smailus D, Moksa M, Chittaranjan S, Rimsza L, Brooks-Wilson A, Spinelli JJ, Ben-Neriah S, Meissner B, Woolcock B, Boyle M, McDonald H, Tam A, Zhao Y, Delaney A, Zeng T, Tse K, Butterfield Y, Birol I, Holt R, Schein J, Horsman DE, Moore R, Jones SJ, Connors JM, Hirst M, Gascoyne RD, Marra MA (2011) Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476:298–303. https://doi.org/10.1038/nature10351 PubMedPubMedCentralCrossRef Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, Johnson NA, Severson TM, Chiu R, Field M, Jackman S, Krzywinski M, Scott DW, Trinh DL, Tamura-Wells J, Li S, Firme MR, Rogic S, Griffith M, Chan S, Yakovenko O, Meyer IM, Zhao EY, Smailus D, Moksa M, Chittaranjan S, Rimsza L, Brooks-Wilson A, Spinelli JJ, Ben-Neriah S, Meissner B, Woolcock B, Boyle M, McDonald H, Tam A, Zhao Y, Delaney A, Zeng T, Tse K, Butterfield Y, Birol I, Holt R, Schein J, Horsman DE, Moore R, Jones SJ, Connors JM, Hirst M, Gascoyne RD, Marra MA (2011) Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476:298–303. https://​doi.​org/​10.​1038/​nature10351 PubMedPubMedCentralCrossRef
93.
Zurück zum Zitat Green MR, Kihira S, Liu CL, Nair RV, Salari R, Gentles AJ, Irish J, Stehr H, Vicente-Dueñas C, Romero-Camarero I, Sanchez-Garcia I, Plevritis SK, Arber DA, Batzoglou S, Levy R, Alizadeh AA (2015) Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proc Natl Acad Sci U S A 112:E1116–E1125. https://doi.org/10.1073/pnas.1501199112 PubMedPubMedCentralCrossRef Green MR, Kihira S, Liu CL, Nair RV, Salari R, Gentles AJ, Irish J, Stehr H, Vicente-Dueñas C, Romero-Camarero I, Sanchez-Garcia I, Plevritis SK, Arber DA, Batzoglou S, Levy R, Alizadeh AA (2015) Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proc Natl Acad Sci U S A 112:E1116–E1125. https://​doi.​org/​10.​1073/​pnas.​1501199112 PubMedPubMedCentralCrossRef
94.
Zurück zum Zitat Li H, Kaminski MS, Li Y, Yildiz M, Ouillette P, Jones S, Fox H, Jacobi K, Saiya-Cork K, Bixby D, Lebovic D, Roulston D, Shedden K, Sabel M, Marentette L, Cimmino V, Chang AE, Malek SN (2014) Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma. Blood 123:1487–1498. https://doi.org/10.1182/blood-2013-05-500264 PubMedPubMedCentralCrossRef Li H, Kaminski MS, Li Y, Yildiz M, Ouillette P, Jones S, Fox H, Jacobi K, Saiya-Cork K, Bixby D, Lebovic D, Roulston D, Shedden K, Sabel M, Marentette L, Cimmino V, Chang AE, Malek SN (2014) Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma. Blood 123:1487–1498. https://​doi.​org/​10.​1182/​blood-2013-05-500264 PubMedPubMedCentralCrossRef
100.
Zurück zum Zitat López-Guillermo A, Cabanillas F, McLaughlin P, Smith T, Hagemeister F, Rodríguez MA, Romaguera JE, Younes A, Sarris AH, Preti HA, Pugh W, Lee MS (1998) The clinical significance of molecular response in indolent follicular lymphomas. Blood 91:2955–2960PubMed López-Guillermo A, Cabanillas F, McLaughlin P, Smith T, Hagemeister F, Rodríguez MA, Romaguera JE, Younes A, Sarris AH, Preti HA, Pugh W, Lee MS (1998) The clinical significance of molecular response in indolent follicular lymphomas. Blood 91:2955–2960PubMed
101.
Zurück zum Zitat López-Guillermo A, Cabanillas F, McLaughlin P, Smith T, Hagemeister F, Rodríguez MA, Romaguera JE, Younes A, Sarris AH, Preti HA, Pugh W, Lee MS (2000) Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC series. Ann Oncol 11(Suppl 1):137–140PubMedCrossRef López-Guillermo A, Cabanillas F, McLaughlin P, Smith T, Hagemeister F, Rodríguez MA, Romaguera JE, Younes A, Sarris AH, Preti HA, Pugh W, Lee MS (2000) Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC series. Ann Oncol 11(Suppl 1):137–140PubMedCrossRef
103.
Zurück zum Zitat Scherer F, Kurtz DM, Newman AM, Stehr H, Craig AF, Esfahani MS, Lovejoy AF, Chabon JJ, Klass DM, Liu CL, Zhou L, Glover C, Visser BC, Poultsides GA, Advani RH, Maeda LS, Gupta NK, Levy R, Ohgami RS, Kunder CA, Diehn M, Alizadeh AA (2016) Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med 8:364ra155. https://doi.org/10.1126/scitranslmed.aai8545 PubMedPubMedCentralCrossRef Scherer F, Kurtz DM, Newman AM, Stehr H, Craig AF, Esfahani MS, Lovejoy AF, Chabon JJ, Klass DM, Liu CL, Zhou L, Glover C, Visser BC, Poultsides GA, Advani RH, Maeda LS, Gupta NK, Levy R, Ohgami RS, Kunder CA, Diehn M, Alizadeh AA (2016) Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med 8:364ra155. https://​doi.​org/​10.​1126/​scitranslmed.​aai8545 PubMedPubMedCentralCrossRef
105.
Zurück zum Zitat Weisdorf DJ, Andersen JW, Glick JH, Oken MM (1992) Survival after relapse of low-grade non-Hodgkin's lymphoma: implications for marrow transplantation. J Clin Oncol 10:942–947PubMedCrossRef Weisdorf DJ, Andersen JW, Glick JH, Oken MM (1992) Survival after relapse of low-grade non-Hodgkin's lymphoma: implications for marrow transplantation. J Clin Oncol 10:942–947PubMedCrossRef
107.
Zurück zum Zitat Bachy E, Brice P, Delarue R, Brousse N, Haioun C, Le Gouill S, Delmer A, Bordessoule D, Tilly H, Corront B, Allard C, Foussard C, Bosly A, Coiffier B, Gisselbrecht C, Solal-Celigny P, Salles G (2010) Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival—a study from the groupe d'etude des lymphomes de l'adulte. J Clin Oncol 28:822–829. https://doi.org/10.1200/JCO.2009.22.7819 PubMedCrossRef Bachy E, Brice P, Delarue R, Brousse N, Haioun C, Le Gouill S, Delmer A, Bordessoule D, Tilly H, Corront B, Allard C, Foussard C, Bosly A, Coiffier B, Gisselbrecht C, Solal-Celigny P, Salles G (2010) Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival—a study from the groupe d'etude des lymphomes de l'adulte. J Clin Oncol 28:822–829. https://​doi.​org/​10.​1200/​JCO.​2009.​22.​7819 PubMedCrossRef
108.
Zurück zum Zitat Luminari S, Biasoli I, Versari A, Rattotti S, Bottelli C, Rusconi C, Merli F, Spina M, Ferreri AJ, Zinzani PL, Gallamini A, Franceschetto A, Boccomini C, Franceschetti S, Salvi F, Raimondo FD, Carella AM, Micol Q, Balzarotti M, Musto P, Federico M (2014) The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). Ann Oncol 25:442–447. https://doi.org/10.1093/annonc/mdt562 PubMedCrossRef Luminari S, Biasoli I, Versari A, Rattotti S, Bottelli C, Rusconi C, Merli F, Spina M, Ferreri AJ, Zinzani PL, Gallamini A, Franceschetto A, Boccomini C, Franceschetti S, Salvi F, Raimondo FD, Carella AM, Micol Q, Balzarotti M, Musto P, Federico M (2014) The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). Ann Oncol 25:442–447. https://​doi.​org/​10.​1093/​annonc/​mdt562 PubMedCrossRef
110.
Zurück zum Zitat Trotman J, Fournier M, Lamy T, Seymour JF, Sonet A, Janikova A, Shpilberg O, Gyan E, Tilly H, Estell J, Forsyth C, Decaudin D, Fabiani B, Gabarre J, Salles B, Van Den Neste E, Canioni D, Garin E, Fulham M, Vander Borght T, Salles G (2011) Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol 29:3194–3200. https://doi.org/10.1200/JCO.2011.35.0736 PubMedCrossRef Trotman J, Fournier M, Lamy T, Seymour JF, Sonet A, Janikova A, Shpilberg O, Gyan E, Tilly H, Estell J, Forsyth C, Decaudin D, Fabiani B, Gabarre J, Salles B, Van Den Neste E, Canioni D, Garin E, Fulham M, Vander Borght T, Salles G (2011) Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol 29:3194–3200. https://​doi.​org/​10.​1200/​JCO.​2011.​35.​0736 PubMedCrossRef
111.
Zurück zum Zitat Dupuis J, Berriolo-Riedinger A, Julian A, Brice P, Tychyj-Pinel C, Tilly H, Mounier N, Gallamini A, Feugier P, Soubeyran P, Colombat P, Laurent G, Berenger N, Casasnovas RO, Vera P, Paone G, Xerri L, Salles G, Haioun C, Meignan M (2012) Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS. J Clin Oncol 30:4317–4322. https://doi.org/10.1200/JCO.2012.43.0934 PubMedCrossRef Dupuis J, Berriolo-Riedinger A, Julian A, Brice P, Tychyj-Pinel C, Tilly H, Mounier N, Gallamini A, Feugier P, Soubeyran P, Colombat P, Laurent G, Berenger N, Casasnovas RO, Vera P, Paone G, Xerri L, Salles G, Haioun C, Meignan M (2012) Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS. J Clin Oncol 30:4317–4322. https://​doi.​org/​10.​1200/​JCO.​2012.​43.​0934 PubMedCrossRef
112.
114.
Zurück zum Zitat Alcantara M, Dupuis J, Mareschal S, Julian A, Cottereau AS, Becker S, Dubois S, Oberic L, Huynh A, Meignan M, Laurent G, Tilly H, Haioun C, Ysebaert L (2015) PET/CT before autologous stem cell transplantation predicts outcome in refractory/relapsed follicular lymphoma. Eur J Nucl Med Mol Imaging 42:215–221. https://doi.org/10.1007/s00259-014-2896-2 PubMedCrossRef Alcantara M, Dupuis J, Mareschal S, Julian A, Cottereau AS, Becker S, Dubois S, Oberic L, Huynh A, Meignan M, Laurent G, Tilly H, Haioun C, Ysebaert L (2015) PET/CT before autologous stem cell transplantation predicts outcome in refractory/relapsed follicular lymphoma. Eur J Nucl Med Mol Imaging 42:215–221. https://​doi.​org/​10.​1007/​s00259-014-2896-2 PubMedCrossRef
115.
Zurück zum Zitat Kostakoglu L, Goy A, Martinelli G, Caballero D, Crump M, Gaidano G, Baetz T, Buckstein R, Fine G, Fingerle-Rowson G, Berge C, Sahin D, Press O, Sehn L (2017) FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study. Leuk Lymphoma 58:372–381. https://doi.org/10.1080/10428194.2016.1196815 PubMedCrossRef Kostakoglu L, Goy A, Martinelli G, Caballero D, Crump M, Gaidano G, Baetz T, Buckstein R, Fine G, Fingerle-Rowson G, Berge C, Sahin D, Press O, Sehn L (2017) FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study. Leuk Lymphoma 58:372–381. https://​doi.​org/​10.​1080/​10428194.​2016.​1196815 PubMedCrossRef
117.
Zurück zum Zitat Luminari S, Galimberti S, Versari A, Biasoli I, Anastasia A, Rusconi C, Ferrari A, Petrini M, Manni M, Federico M (2016) Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi. Haematologica 101:e66–e68. https://doi.org/10.3324/haematol.2015.132811 PubMedPubMedCentralCrossRef Luminari S, Galimberti S, Versari A, Biasoli I, Anastasia A, Rusconi C, Ferrari A, Petrini M, Manni M, Federico M (2016) Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi. Haematologica 101:e66–e68. https://​doi.​org/​10.​3324/​haematol.​2015.​132811 PubMedPubMedCentralCrossRef
118.
Zurück zum Zitat Montoto S, López-Guillermo A, Altés A, Perea G, Ferrer A, Camós M, Villela L, Bosch F, Esteve J, Cervantes F, Bladé J, Nomdedeu B, Campo E, Sierra J, Montserrat E (2004) Predictive value of follicular lymphoma international prognostic index (FLIPI) in patients with follicular lymphoma at first progression. Ann Oncol 15:1484–1489. https://doi.org/10.1093/annonc/mdh406 PubMedCrossRef Montoto S, López-Guillermo A, Altés A, Perea G, Ferrer A, Camós M, Villela L, Bosch F, Esteve J, Cervantes F, Bladé J, Nomdedeu B, Campo E, Sierra J, Montserrat E (2004) Predictive value of follicular lymphoma international prognostic index (FLIPI) in patients with follicular lymphoma at first progression. Ann Oncol 15:1484–1489. https://​doi.​org/​10.​1093/​annonc/​mdh406 PubMedCrossRef
119.
Zurück zum Zitat Pott C, Belada D, Danesi N, Fingerle-Rowson G, Gribben J, Harbron C, Hoster E, Kahl BS, Mundt K, Sebban C, Sehn LH, Cheson BD (2015) Analysis of minimal residual disease in follicular lymphoma patients in Gadolin, a phase III study of obinutuzumab plus bendamustine versus bendamustine in relapsed/refractory indolent non-Hodgkin lymphoma. Blood 126:3978 Pott C, Belada D, Danesi N, Fingerle-Rowson G, Gribben J, Harbron C, Hoster E, Kahl BS, Mundt K, Sebban C, Sehn LH, Cheson BD (2015) Analysis of minimal residual disease in follicular lymphoma patients in Gadolin, a phase III study of obinutuzumab plus bendamustine versus bendamustine in relapsed/refractory indolent non-Hodgkin lymphoma. Blood 126:3978
120.
Zurück zum Zitat Kornacker M, Stumm J, Pott C, Dietrich S, Süssmilch S, Hensel M, Nickelsen M, Witzens-Harig M, Kneba M, Schmitz N, Ho AD, Dreger P (2009) Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up. Ann Oncol 20:722–728. https://doi.org/10.1093/annonc/mdn691 PubMedCrossRef Kornacker M, Stumm J, Pott C, Dietrich S, Süssmilch S, Hensel M, Nickelsen M, Witzens-Harig M, Kneba M, Schmitz N, Ho AD, Dreger P (2009) Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up. Ann Oncol 20:722–728. https://​doi.​org/​10.​1093/​annonc/​mdn691 PubMedCrossRef
121.
Zurück zum Zitat Le Gouill S, De Guibert S, Planche L, Brice P, Dupuis J, Cartron G, Van Hoof A, Casasnovas O, Gyan E, Tilly H, Fruchart C, Deconinck E, Fitoussi O, Gastaud L, Delwail V, Gabarre J, Gressin R, Blanc M, Foussard C, Salles G, GELA and GOELAMS. (2011) Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study. Haematologica 96:1128–1135. https://doi.org/10.3324/haematol.2010.030320 PubMedPubMedCentralCrossRef Le Gouill S, De Guibert S, Planche L, Brice P, Dupuis J, Cartron G, Van Hoof A, Casasnovas O, Gyan E, Tilly H, Fruchart C, Deconinck E, Fitoussi O, Gastaud L, Delwail V, Gabarre J, Gressin R, Blanc M, Foussard C, Salles G, GELA and GOELAMS. (2011) Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study. Haematologica 96:1128–1135. https://​doi.​org/​10.​3324/​haematol.​2010.​030320 PubMedPubMedCentralCrossRef
122.
Zurück zum Zitat Scholz CW, Pinto A, Linkesch W, Lindén O, Viardot A, Keller U, Hess G, Lastoria S, Lerch K, Frigeri F, Arcamone M, Stroux A, Frericks B, Pott C, Pezzutto A (2013) (90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial. J Clin Oncol 31:308–313. https://doi.org/10.1200/JCO.2011.41.1553 PubMedCrossRef Scholz CW, Pinto A, Linkesch W, Lindén O, Viardot A, Keller U, Hess G, Lastoria S, Lerch K, Frigeri F, Arcamone M, Stroux A, Frericks B, Pott C, Pezzutto A (2013) (90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial. J Clin Oncol 31:308–313. https://​doi.​org/​10.​1200/​JCO.​2011.​41.​1553 PubMedCrossRef
124.
Zurück zum Zitat Tarella C, Gueli A, Delaini F, Rossi A, Barbui AM, Gritti G, Boschini C, Caracciolo D, Bruna R, Ruella M, Gottardi D, Passera R, Rambaldi A (2014) Rate of primary refractory disease in B and T-cell non-Hodgkin's lymphoma: correlation with long-term survival. PLoS One 9:e106745PubMedPubMedCentralCrossRef Tarella C, Gueli A, Delaini F, Rossi A, Barbui AM, Gritti G, Boschini C, Caracciolo D, Bruna R, Ruella M, Gottardi D, Passera R, Rambaldi A (2014) Rate of primary refractory disease in B and T-cell non-Hodgkin's lymphoma: correlation with long-term survival. PLoS One 9:e106745PubMedPubMedCentralCrossRef
125.
Zurück zum Zitat Cheah CY, Chihara D, Ahmed M, Davis RE, Nastoupil LJ, Phansalkar K, Hagemeister FB, Fayad LE, Westin JR, Oki Y, Fanale MA, Romaguera JE, Wang ML, Lee H, Turturro F, Samaniego F, Rodriguez MA, Neelapu SS, Fowler NH (2016) Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Ann Oncol 27:895–901. https://doi.org/10.1007/s00277-016-2690-2 PubMedCrossRef Cheah CY, Chihara D, Ahmed M, Davis RE, Nastoupil LJ, Phansalkar K, Hagemeister FB, Fayad LE, Westin JR, Oki Y, Fanale MA, Romaguera JE, Wang ML, Lee H, Turturro F, Samaniego F, Rodriguez MA, Neelapu SS, Fowler NH (2016) Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Ann Oncol 27:895–901. https://​doi.​org/​10.​1007/​s00277-016-2690-2 PubMedCrossRef
126.
Zurück zum Zitat Lansigan F, Barak I, Pitcher BN, Jung SH, Cheson B, Czuczman MS, Grant BW, Martin P, Hsi ED, Schoder H, Smith SE, Bartlett NL, Leonard JP, Blum K (2016) Early relapse of follicular lymphoma after rituximab-based biologic doublet upfront therapy is associated with increased risk of death: a combined analysis from CALGB studies 50402, 50701 and 50803 (alliance). Blood 128:2953 Lansigan F, Barak I, Pitcher BN, Jung SH, Cheson B, Czuczman MS, Grant BW, Martin P, Hsi ED, Schoder H, Smith SE, Bartlett NL, Leonard JP, Blum K (2016) Early relapse of follicular lymphoma after rituximab-based biologic doublet upfront therapy is associated with increased risk of death: a combined analysis from CALGB studies 50402, 50701 and 50803 (alliance). Blood 128:2953
127.
Zurück zum Zitat Maurer MJ, Bachy E, Ghesquières H, Ansell SM, Nowakowski GS, Thompson CA, Inwards DJ, Allmer C, Chassagne-Clément C, Nicolas-Virelizier E, Sebban C, Lebras L, Sarkozy C, Macon WR, Feldman AL, Syrbu SI, Traverse-Glehan A, Coiffier B, Slager SL, Weiner GJ, Witzig TE, Habermann TM, Salles G, Cerhan JR, Link BK (2016) Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am J Hematol 91:1096–1101. https://doi.org/10.1002/ajh.24492 PubMedPubMedCentralCrossRef Maurer MJ, Bachy E, Ghesquières H, Ansell SM, Nowakowski GS, Thompson CA, Inwards DJ, Allmer C, Chassagne-Clément C, Nicolas-Virelizier E, Sebban C, Lebras L, Sarkozy C, Macon WR, Feldman AL, Syrbu SI, Traverse-Glehan A, Coiffier B, Slager SL, Weiner GJ, Witzig TE, Habermann TM, Salles G, Cerhan JR, Link BK (2016) Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am J Hematol 91:1096–1101. https://​doi.​org/​10.​1002/​ajh.​24492 PubMedPubMedCentralCrossRef
128.
Zurück zum Zitat Murakami S, Kato H, Higuchi Y, Yamamoto K, Yamamoto H, Saito T, Taji H, Yatabe Y, Nakamura S, Kinoshita T (2016) Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy. Ann Hematol 95:1259–1269. https://doi.org/10.1007/s00277-016-2690-2 PubMedCrossRef Murakami S, Kato H, Higuchi Y, Yamamoto K, Yamamoto H, Saito T, Taji H, Yatabe Y, Nakamura S, Kinoshita T (2016) Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy. Ann Hematol 95:1259–1269. https://​doi.​org/​10.​1007/​s00277-016-2690-2 PubMedCrossRef
129.
Zurück zum Zitat Prochazka VK, Papajik T, Janikova A, Belada D, Kozak T, Salek D, Sykorova A, Mocikova H, Campr V, Dlouha J, Fuerst T, Trneny M (2016) Early progression after R-CHOP in follicular lymphoma: key role for the maintenance therapy. Blood 128:1779CrossRef Prochazka VK, Papajik T, Janikova A, Belada D, Kozak T, Salek D, Sykorova A, Mocikova H, Campr V, Dlouha J, Fuerst T, Trneny M (2016) Early progression after R-CHOP in follicular lymphoma: key role for the maintenance therapy. Blood 128:1779CrossRef
130.
Zurück zum Zitat Magnano L, Alonso-Alvarez S, Alcobenda M, Rivas-Delgado A, Andrade-Campos M, Rodríguez G, Sancho JM, Mercadal S, Salar A, Arranz R, Terol MJ, Jiménez A, González de Villambrosia S, Bello JL, López L, Novelli S, Muntañola A, De Cabo E, Infante MS, Pardal E, Canales M, González M, Martín A, Caballero D, López-Guillermo A (2016) Los pacientes con linfoma folicular que alcanzan respuesta completa y la mantienen a los 30 meses presentan una supervivencia similar a la poblacion general de igual edad y sexo. Estudio del grupo GELTAMO. Haematologica 101S4:CO-012 Magnano L, Alonso-Alvarez S, Alcobenda M, Rivas-Delgado A, Andrade-Campos M, Rodríguez G, Sancho JM, Mercadal S, Salar A, Arranz R, Terol MJ, Jiménez A, González de Villambrosia S, Bello JL, López L, Novelli S, Muntañola A, De Cabo E, Infante MS, Pardal E, Canales M, González M, Martín A, Caballero D, López-Guillermo A (2016) Los pacientes con linfoma folicular que alcanzan respuesta completa y la mantienen a los 30 meses presentan una supervivencia similar a la poblacion general de igual edad y sexo. Estudio del grupo GELTAMO. Haematologica 101S4:CO-012
131.
Zurück zum Zitat Shi Q, Flowers CR, Hiddemann W, Marcus R, Herold M, Hagenbeek A, Kimby E, Hochster H, Vitolo U, Peterson BA, Gyan E, Ghielmini M, Nielsen T, De Bedout S, Fu T, Valente N, Fowler NH, Hoster E, Ladetto M, Morschhauser F, Zucca E, Salles G, Sargent DJ (2016) Thirty-month complete response as a surrogate end point in first-line follicular lymphoma therapy: An individual patient-level analysis of multiple randomized trials. J Clin Oncol 35:552–560PubMedCrossRef Shi Q, Flowers CR, Hiddemann W, Marcus R, Herold M, Hagenbeek A, Kimby E, Hochster H, Vitolo U, Peterson BA, Gyan E, Ghielmini M, Nielsen T, De Bedout S, Fu T, Valente N, Fowler NH, Hoster E, Ladetto M, Morschhauser F, Zucca E, Salles G, Sargent DJ (2016) Thirty-month complete response as a surrogate end point in first-line follicular lymphoma therapy: An individual patient-level analysis of multiple randomized trials. J Clin Oncol 35:552–560PubMedCrossRef
133.
Zurück zum Zitat Okosun J, Bödör C, Wang J, Araf S, Yang CY, Pan C, Boller S, Cittaro D, Bozek M, Iqbal S, Matthews J, Wrench D, Marzec J, Tawana K, Popov N, O'Riain C, O'Shea D, Carlotti E, Davies A, Lawrie CH, Matolcsy A, Calaminici M, Norton A, Byers RJ, Mein C, Stupka E, Lister TA, Lenz G, Montoto S, Gribben JG, Fan Y, Grosschedl R, Chelala C, Fitzgibbon J (2014) Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet 46:176–181. https://doi.org/10.1038/ng.2856 PubMedCrossRef Okosun J, Bödör C, Wang J, Araf S, Yang CY, Pan C, Boller S, Cittaro D, Bozek M, Iqbal S, Matthews J, Wrench D, Marzec J, Tawana K, Popov N, O'Riain C, O'Shea D, Carlotti E, Davies A, Lawrie CH, Matolcsy A, Calaminici M, Norton A, Byers RJ, Mein C, Stupka E, Lister TA, Lenz G, Montoto S, Gribben JG, Fan Y, Grosschedl R, Chelala C, Fitzgibbon J (2014) Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet 46:176–181. https://​doi.​org/​10.​1038/​ng.​2856 PubMedCrossRef
135.
Zurück zum Zitat Link BK, Maurer MJ, Nowakowski GS, Ansell SM, Macon WR, Syrbu SI, Slager SL, Thompson CA, Inwards DJ, Johnston PB, Colgan JP, Witzig TE, Habermann TM, Cerhan JR (2013) Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol 31:3272–3278. https://doi.org/10.1200/JCO.2012.48.3990 PubMedPubMedCentralCrossRef Link BK, Maurer MJ, Nowakowski GS, Ansell SM, Macon WR, Syrbu SI, Slager SL, Thompson CA, Inwards DJ, Johnston PB, Colgan JP, Witzig TE, Habermann TM, Cerhan JR (2013) Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol 31:3272–3278. https://​doi.​org/​10.​1200/​JCO.​2012.​48.​3990 PubMedPubMedCentralCrossRef
136.
Zurück zum Zitat Sarkozy C, Trneny M, Xerri L, Wickham N, Feugier P, Leppa S, Brice P, Soubeyran P, Gomes Da Silva M, Mounier C, Offner F, Dupuis J, Caballero D, Canioni D, Paula M, Delarue R, Zachee P, Seymour J, Salles G, Tilly H (2016) Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial. J Clin Oncol 34:2575–2582. https://doi.org/10.1200/JCO.2015.65.7163 PubMedCrossRef Sarkozy C, Trneny M, Xerri L, Wickham N, Feugier P, Leppa S, Brice P, Soubeyran P, Gomes Da Silva M, Mounier C, Offner F, Dupuis J, Caballero D, Canioni D, Paula M, Delarue R, Zachee P, Seymour J, Salles G, Tilly H (2016) Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial. J Clin Oncol 34:2575–2582. https://​doi.​org/​10.​1200/​JCO.​2015.​65.​7163 PubMedCrossRef
139.
Zurück zum Zitat Glas AM, Knoops L, Delahaye L, Kersten MJ, Kibbelaar RE, Wessels LA, van Laar R, van Krieken JH, Baars JW, Raemaekers J, Kluin PM, van't Veer LJ, de Jong D (2007) Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 25:390–398. https://doi.org/10.1200/JCO.2006.06.1648 PubMedCrossRef Glas AM, Knoops L, Delahaye L, Kersten MJ, Kibbelaar RE, Wessels LA, van Laar R, van Krieken JH, Baars JW, Raemaekers J, Kluin PM, van't Veer LJ, de Jong D (2007) Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 25:390–398. https://​doi.​org/​10.​1200/​JCO.​2006.​06.​1648 PubMedCrossRef
142.
Zurück zum Zitat Federico M, Caballero D, Marcheselli L, Tarantino V, Sarkozy C, Lopez-Guillermo A, Wondergem M, Kimby E, Rusconi C, Zucca E, Montoto S, da Silva MG, Aurer I, Paszkiewicz-Kozik E, Cartron G, Morschhauser F, Alcoceba M, Chamuleau M, Lockmer S, Minoia C, Issa D, Alonso S, Conte L, Salles G, Coiffier B (2017) The risk of transformation of follicular lympgoma “transformed” by rituximab: the aristotle study promoted by the European Lymphoma Institute. Hematol Oncol 35S2:115–116. https://doi.org/10.1002/hon.2437_104 CrossRef Federico M, Caballero D, Marcheselli L, Tarantino V, Sarkozy C, Lopez-Guillermo A, Wondergem M, Kimby E, Rusconi C, Zucca E, Montoto S, da Silva MG, Aurer I, Paszkiewicz-Kozik E, Cartron G, Morschhauser F, Alcoceba M, Chamuleau M, Lockmer S, Minoia C, Issa D, Alonso S, Conte L, Salles G, Coiffier B (2017) The risk of transformation of follicular lympgoma “transformed” by rituximab: the aristotle study promoted by the European Lymphoma Institute. Hematol Oncol 35S2:115–116. https://​doi.​org/​10.​1002/​hon.​2437_​104 CrossRef
144.
Zurück zum Zitat Soumerai JD, Bantilan KS, Ni A, Batlevi C, Alperovich A, Smith K, Ying Z, Copeland AR, Matasar MJ, Straus DJ, Gerecitano JF, Hamlin PA, Horwitz SM, Portlock CS, Palomba ML, Moskowitz CH, Moskowitz AJ, Noy A, Sauter CS, Kumar A, Intlekofer AM, Caron P, Drullinsky P, Younes A, Zelenetz AD (2016) Intervention versus observation: what is the appropriate endpoint? Assessment of endpoints in patients with advanced stage follicular lymphoma who are initially observed. Blood 128:1777CrossRef Soumerai JD, Bantilan KS, Ni A, Batlevi C, Alperovich A, Smith K, Ying Z, Copeland AR, Matasar MJ, Straus DJ, Gerecitano JF, Hamlin PA, Horwitz SM, Portlock CS, Palomba ML, Moskowitz CH, Moskowitz AJ, Noy A, Sauter CS, Kumar A, Intlekofer AM, Caron P, Drullinsky P, Younes A, Zelenetz AD (2016) Intervention versus observation: what is the appropriate endpoint? Assessment of endpoints in patients with advanced stage follicular lymphoma who are initially observed. Blood 128:1777CrossRef
147.
Zurück zum Zitat Morschhauser F, Salles G, McKay P, Tilly H, Schmitt A, Gerecitano J, Johnson P, Le Gouill S, Dickinson MJ, Fruchart C, Lamy T, Chaidos A, Jurczak W, Opat S, Radford J, Zinzani PL, Assouline S, Cartron G, Clawson A, Picazio N, Ribich S, Blakemore SJ, Larus J, Miao H, Ho PT, Ribrag V Interim report from a phase 2 multicenter study of tazemetostat, an EZH2 inhibitor in patients with relapsed or refractory B-cell non-Hodgkin lymphomas. Hematol Oncol 35S2:24–25. https://doi.org/10.1002/hon.2437_3 Morschhauser F, Salles G, McKay P, Tilly H, Schmitt A, Gerecitano J, Johnson P, Le Gouill S, Dickinson MJ, Fruchart C, Lamy T, Chaidos A, Jurczak W, Opat S, Radford J, Zinzani PL, Assouline S, Cartron G, Clawson A, Picazio N, Ribich S, Blakemore SJ, Larus J, Miao H, Ho PT, Ribrag V Interim report from a phase 2 multicenter study of tazemetostat, an EZH2 inhibitor in patients with relapsed or refractory B-cell non-Hodgkin lymphomas. Hematol Oncol 35S2:24–25. https://​doi.​org/​10.​1002/​hon.​2437_​3
150.
Zurück zum Zitat Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD, Thompson CA, Rivera CE, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Gascoyne RD, Habermann TM, Witzig TE (2015) Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study. J Clin Oncol 33:251–257. https://doi.org/10.1200/JCO.2014.55.5714 PubMedCrossRef Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD, Thompson CA, Rivera CE, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Gascoyne RD, Habermann TM, Witzig TE (2015) Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study. J Clin Oncol 33:251–257. https://​doi.​org/​10.​1200/​JCO.​2014.​55.​5714 PubMedCrossRef
151.
Zurück zum Zitat Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J, de Vos S, Goy A, Kenkre VP, Barr PM, Blum KA, Shustov A, Advani R, Fowler NH, Vose JM, Elstrom RL, Habermann TM, Barrientos JC, McGreivy J, Fardis M, Chang BY, Clow F, Munneke B, Moussa D, Beaupre DM, Staudt LM (2015) Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 21:922–926. https://doi.org/10.1038/nm.3884 PubMedCrossRef Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J, de Vos S, Goy A, Kenkre VP, Barr PM, Blum KA, Shustov A, Advani R, Fowler NH, Vose JM, Elstrom RL, Habermann TM, Barrientos JC, McGreivy J, Fardis M, Chang BY, Clow F, Munneke B, Moussa D, Beaupre DM, Staudt LM (2015) Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 21:922–926. https://​doi.​org/​10.​1038/​nm.​3884 PubMedCrossRef
Metadaten
Titel
Current prognostic and predictive factors in follicular lymphoma
verfasst von
Marc Sorigue
Juan-Manuel Sancho
Publikationsdatum
14.10.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 2/2018
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-017-3154-z

Weitere Artikel der Ausgabe 2/2018

Annals of Hematology 2/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.